Lipidomic Evaluation of Feline Neurologic Disease after AAV Gene Therapy
Open Access
- 1 September 2017
- journal article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 6, 135-142
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01 HD060576, R01 NS081985, F32 NS080488)
- NIH (UL1 TR000448)
This publication has 29 references indexed in Scilit:
- Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergeticsBrain, 2014
- Sustained Normalization of Neurological Disease after Intracranial Gene Therapy in a Feline ModelScience Translational Medicine, 2014
- Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson’s DiseaseJournal of Parkinson’s Disease, 2014
- Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using MetabolomicsPLOS ONE, 2013
- Development and validation of sensitive and selective LC–MS/MS methods for the determination of BMS-708163, a γ-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ionsJournal of Chromatography B, 2010
- Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff diseaseHuman Molecular Genetics, 2008
- Complete Correction of Enzymatic Deficiency and Neurochemistry in the GM1-gangliosidosis Mouse Brain by Neonatal Adeno-associated Virus–mediated Gene DeliveryMolecular Therapy, 2007
- Sphingolipid profile in the CNS of the twitcher (globoid cell leukodystrophy) mouse: a lipidomics approach.2003
- Ganglioside GM3 Participates in the Pathological Conditions of Insulin ResistanceJournal of Biological Chemistry, 2002
- Neuronal GM 1 Gangliosidosis in a Siamese Cat with β-Galactosidase DeficiencyScience, 1971